Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 9 results.
User Information
Export Records
  1. 1.   Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
  2. Huang, Chen; Chen, Lijun; Savage, Sara R.; Eguez, Rodrigo Vargas; Dou, Yongchao; Li, Yize; Leprevost, Felipe da Veiga; Jaehnig, Eric J.; Lei, Jonathan T.; Wen, Bo; Schnaubelt, Michael; Krug, Karsten; Song, Xiaoyu; Cieslik, Marcin; Chang, Hui-Yin; Wyczalkowski, Matthew A.; Li, Kai; Colaprico, Antonio; Li, Qing Kay; Clark, David J.; Hu, Yingwei; Cao, Liwei; Pan, Jianbo; Wang, Yuefan; Cho, Kyung-Cho; Shi, Zhiao; Liao, Yuxing; Jiang, Wen; Anurag, Meenakshi; Ji, Jiayi; Yoo, Seungyeul; Zhou, Daniel Cui; Liang, Wen-Wei; Wendl, Michael; Vats, Pankaj; Carr, Steven A.; Mani, D. R.; Zhang, Zhen; Qian, Jiang; Chen, Xi S.; Pico, Alexander R.; Wang, Pei; Chinnaiyan, Arul M.; Ketchum, Karen A.; Kinsinger, Christopher R.; Robles, Ana; An, Eunkyung; Hiltke, Tara; Mesri, Mehdi; Thiagarajan,Mathangi; Weaver, Alissa M.; Sikora, Andrew G.; Lubinski, Jan; Wierzbicka, Malgorzata; Wiznerowicz, Maciej; Satpathy, Shankha; Gillette, Michael A.; Miles, George; Ellis, Matthew J.; Omenn, Gilbert S.; Rodriguez, Henry; Boja, Emily S.; Dhanasekaran, Saravana M.; Ding, Li; Nesvizhskii, Alexey; El-Naggar, Adel K.; Chan, Daniel W.; Zhang, Hui; Zhang, Bing
  3. Cancer Cell. 2021, Mar 8; 39(3): 361-379.
  1. 2.   Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
  2. Lampert, Erika J.; Zimmer, Alexandra; Padget, Michelle; Cimino-Mathews, Ashley; Nair, Jayakumar R.; Liu, Yingmiao; Swisher, Elizabeth M.; Hodge, James W.; Nixon, Andrew B.; Villanueva,Erin; Bagheri, Mohammad H.; Levy, Elliott; Radke, Marc R.; Lipkowitz, Stanley; Annunziata, Christina M.; Taube, Janis M.; Steinberg, Seth M.; Lee, Jung-Min
  3. CLINICAL CANCER RESEARCH. 2020, AUG 15; 26(16): 4268-4279.
  1. 3.   Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  2. Chae, Young K; Hong, Fangxin; Vaklavas, Christos; Cheng, Heather H; Hammerman, Peter; Mitchell, Edith P; Zwiebel, James A; Ivy, S Percy; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Mansfield, Aaron; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JUL 20; 38(21): 2407-+.
  1. 4.   Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model
  2. Zhu, Guangwei; Zhao, Ming; Han, Qinghong; Tan, Yuying; Sun, Yu; Bouvet, Michael; Clary, Bryan; Singh,Shree Ram; Ye, Jianxin; Hoffman, Robert M
  3. Translational oncology. 2020, Mar 03; 13(3): 100739.
  1. 5.   Antibody-drug conjugates for cancer
  2. Chau, Cindy H.; Steeg,Pat; Figg, William D.
  3. Lancet (London, England). 2019, Aug 31; 394(10200): 793-804.
  1. 6.   Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors
  2. Strauss, Julius; Heery, Christopher R.; Schlom, Jeffrey; Madan, Ravi A.; Cao, Liang; Kang, Zhigang; Lamping, Elizabeth; Marte, Jennifer L.; Donahue, Renee N.; Grenga, Italia; Cordes, Lisa; Christensen, Olaf; Mahnke, Lisa; Helwig, Christoph; Gulley, James L.
  3. Clinical Cancer Research. 2018, Mar 15; 24(6): 1287-1295.
  1. 7.   The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
  2. Gril, B.; Palmieri, D.; Qian, Y.; Anwar, T.; Ileva, L.; Bernardo, M.; Choyke, P.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S.
  3. Plos One. 2011, Oct; 6(10): 11.
  1. 8.   Lack of Effect from a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir
  2. Dlamini, J. N.; Hu, Z. H.; Somaroo, H.; Highbarger, H. C.; Follmann, D. A.; Dewar, R. L.; Pau, A. K.
  3. Pharmacotherapy. 2011, Feb; 31(2): 158-163.
  1. 9.   Temporal characteristics of botulinum neurotoxin therapy
  2. Lebeda, F. J.; Cer, R. Z.; Stephens, R. M.; Mudunuri, U.
  3. Expert Review of Neurotherapeutics. 2010, Jan; 10(1): 93-103.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel